摘要
目的分析左氧氟沙星治疗耐多药肺结核感染的疗效及安全性。方法选取2014年1月至2016年1月我院收治的耐多药肺结核感染患者86例为研究对象,随机分为对照组和观察组,各43例。两组患者均给予联合用药,观察组患者在联合用药的基础上给予口服左氧氟沙星片治疗,对照组患者在联合用药的基础上给予口服氧氟沙星治疗,治疗21个月后观察比较两组患者的治疗效果。结果观察组患者治疗3、18个月后抗酸杆菌转阴率分别是55.81%、83.72%,分别高于对照组的41.86%、67.44%,差异有统计学意义(P<0.05);治疗过程中,观察组患者的不良反应发生率为20.93%,低于对照组的37.21%,差异有统计学意义(P<0.05);观察组患者总有效率为90.70%,高于对照组的74.42%,差异有统计学意义(P<0.05)。结论左氧氟沙星治疗耐多药肺结核具有良好的疗效,能降低患者不良反应发生率和结核分支杆菌感染率。
Objective To evaluate the efficacy and safely of levofloxacin in the treatment of mulli drug resistant pulmonary tuberculosis. Methods Eighty -six cases of multi drug resistant pulmonary tuberculosis in our hospital from January 2014 to January 2016 were randomly divided into control group and treatment group, with 43 cases in each group. Both groups were given combined therapy, patients in the observation group added oral levofloxacin tablets, and patients in the control group added oral ofloxacin tablets, the treatment effect was compared between the two groups after 21 months. Results The rate of acid fast bacilli in the observation group after treatment for 3 months and 18 months were 55.81%, 83.72% respectively, which were significantly higher than 41.86%, 67.44% of the control group, the differences were statistically significant （ P〈0.05）. The adverse reactions during treatment rate in the observation group was 20.93%, which was less than 37.21% in the control group （ P〈0.05）. The total effective rate of the observation group was 90.70%, which was higher than 74.42% of the control group （ P〈0.05）. Conclusion Levofloxacin has a good effect in the treatment of multi drug resistant pulmonary tuberculosis, which can reduce the incidence of adverse reactions and mycobacterium tuberculosis infection rate.
出处
《临床医学研究与实践》
2017年第18期43-44,共2页
Clinical Research and Practice
关键词
左氧氟沙星
耐多药肺结核
安全性
levofloxacin
multi drug resistant pulmonary tuberculosis
safety
